Ribociclib therapy in peritoneal carcinomatosis secondary to HER2‐negative metastatic breast cancer: A clinical case with a positive outcome
| Autor: | Lucia Stocchi, Chiara Massaioli, Stefania Guarino |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Receptor ErbB-2 medicine.drug_class Aminopyridines Breast Neoplasms Peritoneal Effusion 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Breast cancer Antineoplastic Combined Chemotherapy Protocols Internal Medicine medicine Humans Peritoneal Neoplasms business.industry Letrozole Cancer medicine.disease Metastatic breast cancer Peritoneal carcinomatosis Receptors Estrogen Oncology Purines Estrogen 030220 oncology & carcinogenesis Concomitant Female Surgery Radiology Receptors Progesterone business medicine.drug |
| Zdroj: | The Breast Journal. 26:1808-1810 |
| ISSN: | 1524-4741 1075-122X |
| DOI: | 10.1111/tbj.13940 |
| Popis: | Although metastatic breast cancer can be fatal, a series of randomized double-blind placebo-controlled phase 3 trials (MONALEESA studies) have shown that ribociclib is an effective anticancer drug for the treatment of advanced breast cancer with bones, liver, lungs, and brain as major metastatic sites. Here, we report the clinical case of a woman with peritoneal carcinomatosis secondary to HER2-negative estrogen receptor-positive breast cancer successfully treated with ribociclib and letrozole. After 9-month follow-up, total body computed tomography imaging showed resolution of hypodense areas surrounding the hepatic hilus with concomitant reduction in both bile duct dilatation and peritoneal effusion, and abdominal lymphadenopathy was excluded. Notably, therapy was well tolerated throughout the treatment with no side effects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |